ViiV Healthcare presents positive data showing Vocabria (cabotegravir) and Rekambys (rilpivirine) can be successfully implemented across a range of European healthcare settings

Back to the "HIV and Co-Infections News" list
  • Healthcare teams from diverse European HIV clinics reported that the implementation of the complete long-acting regimen was acceptable, appropriate, and feasible, with the majority of practices achieving optimal implementation within one to three months
  • 81% of people living with HIV who participated in the study reported that the complete long-acting regimen was less stigmatising than daily oral treatment

Read the full press release here.

 

Get involved

Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?

Subscribe

Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.